ArticleEuropean journal of nuclear medicine and molecular imaging2026
The MIBI is dead, long live the MIBI: revisiting [99mTc]Tc-Sestamibi thyroid scintigraphy in the era of ultrasound, cytology, molecular diagnostic, and 18 F-FDG PET/CT.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[99mTc]Tc-sestamibi (MIBI) thyroid scintigraphy has experienced fluctuating clinical relevance, overshadowed by the rise of ultrasound, cytology, molecular diagnostics, and FDG PET/CT. However, recent evidence highlights a reinvigorated role for MIBI in specific clinical niches, notably in indeterminate thyroid nodules and iodine-induced thyroid dysfunctions. Our opinion paper synthetizes the biological background of thyroid imaging with MIBI, including semi-quantitative analysis. Current clinical indications and clinical results are discussed taking into account the emerging role of 18 F-FDG PET/CT in the field of cytologically indeterminate thyroid nodules offering a balanced perspective on integrating MIBI into modern thyroid diagnostics.
Indexed as
Identifiers
41105224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.